AI Engines For more Details: Perplexity Kagi Labs You
Asthma: Racepinephrine is commonly used to provide quick relief of asthma symptoms, such as wheezing, shortness of breath, and chest tightness. It works by relaxing the muscles in the airways, thereby opening them up and making breathing easier.
Bronchospasm: Racepinephrine is effective in relieving bronchospasm, which is the sudden constriction of the airway muscles leading to difficulty breathing. Bronchospasm can occur in conditions such as asthma, chronic obstructive pulmonary disease (COPD), and allergic reactions.
Chronic Obstructive Pulmonary Disease (COPD): Racepinephrine may be used as a bronchodilator in the management of COPD exacerbations to improve airflow and alleviate symptoms such as coughing, wheezing, and shortness of breath.
Exercise-Induced Bronchospasm (EIB): People with EIB experience bronchospasm during or after physical exertion. Racepinephrine can be used before exercise to prevent or reduce the severity of exercise-induced bronchospasm.
Allergic Reactions: Racepinephrine may be used in the treatment of acute allergic reactions, such as anaphylaxis, to help open up the airways and improve breathing in individuals experiencing severe respiratory distress.
Respiratory Distress: In emergency situations, racepinephrine may be administered to individuals experiencing acute respiratory distress, including situations where there is upper airway obstruction or severe respiratory compromise.
Nebulization Therapy: Racepinephrine solution can be administered via nebulization, a process of converting the medication into a fine mist that is inhaled into the lungs. Nebulized racepinephrine is often used in hospital settings for acute respiratory interventions.
Upper Airway Obstruction: Racepinephrine may be used as part of the treatment regimen for upper airway obstruction, such as croup or epiglottitis, to help reduce airway swelling and improve airflow.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 1.3 | 1.3 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 1.8 | 0.3 | 5 |
| Allergies | 1.2 | 0.5 | 1.4 |
| Allergy to milk products | 0.5 | 0.7 | -0.4 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 1.5 | 2 | -0.33 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 0.6 | |
| Ankylosing spondylitis | 1.2 | 0.9 | 0.33 |
| Anorexia Nervosa | 0.9 | 1.9 | -1.11 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 2.1 | 1.1 | 0.91 |
| Atherosclerosis | 0.9 | 0.9 | 0 |
| Atrial fibrillation | 1.6 | 0.7 | 1.29 |
| Autism | 4.3 | 3.6 | 0.19 |
| Autoimmune Disease | 0.3 | 0.7 | -1.33 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.9 | 0.9 | |
| Bipolar Disorder | 0.9 | 0.5 | 0.8 |
| Brain Trauma | 0.3 | 0.8 | -1.67 |
| Cancer (General) | 0.7 | -0.7 | |
| Carcinoma | 1 | 0.7 | 0.43 |
| Celiac Disease | 2 | 0.7 | 1.86 |
| Cerebral Palsy | 0.8 | 0.8 | 0 |
| Chronic Fatigue Syndrome | 1.4 | 2.4 | -0.71 |
| Chronic Kidney Disease | 1.3 | 0.5 | 1.6 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.8 | -1 |
| Chronic Urticaria (Hives) | 0.5 | 0.6 | -0.2 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.8 | -0.14 |
| Cognitive Function | 1 | 1 | 0 |
| Colorectal Cancer | 3.7 | 1.3 | 1.85 |
| Constipation | 1 | 0.5 | 1 |
| Coronary artery disease | 0.9 | 1.4 | -0.56 |
| COVID-19 | 2.5 | 2.7 | -0.08 |
| Crohn's Disease | 4.2 | 1.9 | 1.21 |
| Cushing's Syndrome (hypercortisolism) | 1 | -1 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 0.6 | 1.1 | -0.83 |
| Denture Wearers Oral Shifts | 0.4 | 0.4 | |
| Depression | 3.6 | 2.5 | 0.44 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.1 | 1.2 | -0.09 |
| Endometriosis | 1 | 0.5 | 1 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 1.8 | 1.3 | 0.38 |
| erectile dysfunction | 0.5 | 0.5 | |
| Fibromyalgia | 1.8 | 0.5 | 2.6 |
| Functional constipation / chronic idiopathic constipation | 2.6 | 2.1 | 0.24 |
| gallstone disease (gsd) | 1.8 | 0.5 | 2.6 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 0.3 | 3.33 |
| Generalized anxiety disorder | 1.2 | 0.8 | 0.5 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.2 | 2 |
| Graves' disease | 0.7 | 1.1 | -0.57 |
| Gulf War Syndrome | 0.5 | 0.6 | -0.2 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 1.4 | 0.3 | 3.67 |
| Heart Failure | 1.8 | 0.5 | 2.6 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 1.4 | 1.4 | |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| hyperglycemia | 0.1 | 0.7 | -6 |
| hypertension (High Blood Pressure | 1.6 | 1.7 | -0.06 |
| Hypoxia | 1.6 | 1.6 | |
| IgA nephropathy (IgAN) | 1 | 1.3 | -0.3 |
| Inflammatory Bowel Disease | 3.9 | 2.6 | 0.5 |
| Insomnia | 0.7 | 1.1 | -0.57 |
| Intelligence | 0.5 | 0.5 | |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 2.5 | 2.4 | 0.04 |
| ischemic stroke | 1 | 0.8 | 0.25 |
| Liver Cirrhosis | 2.5 | 1.3 | 0.92 |
| Long COVID | 2.3 | 1.3 | 0.77 |
| Low bone mineral density | 0.5 | -0.5 | |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.5 | 0.3 | 0.67 |
| ME/CFS without IBS | 1.1 | 0.9 | 0.22 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 3 | 3 | 0 |
| Mood Disorders | 3.6 | 2.4 | 0.5 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.4 | |
| Multiple Sclerosis | 2.4 | 3.6 | -0.5 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 1.3 | -1.3 | |
| Neuropathy (all types) | 0.3 | 1 | -2.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.3 | 0.8 | 0.63 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 2.4 | 3.1 | -0.29 |
| obsessive-compulsive disorder | 2.3 | 1.2 | 0.92 |
| Osteoarthritis | 1.4 | 0.6 | 1.33 |
| Osteoporosis | 1 | 0.6 | 0.67 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 2.5 | 2 | 0.25 |
| Polycystic ovary syndrome | 4.8 | 1.3 | 2.69 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.5 | -0.67 |
| Primary sclerosing cholangitis | 1.2 | 1.8 | -0.5 |
| Psoriasis | 1.1 | 1.9 | -0.73 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.2 | 1.6 | 0.38 |
| Rosacea | 0.7 | -0.7 | |
| Schizophrenia | 1.9 | 1.5 | 0.27 |
| Sjögren syndrome | 0.7 | 0.7 | 0 |
| Sleep Apnea | 0.8 | -0.8 | |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.8 | |
| Stress / posttraumatic stress disorder | 1.5 | 1.3 | 0.15 |
| Systemic Lupus Erythematosus | 2.4 | 0.5 | 3.8 |
| Tic Disorder | 1 | 1 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 2 | 2 | 0 |
| Type 2 Diabetes | 3.7 | 3 | 0.23 |
| Ulcerative colitis | 3.2 | 2.7 | 0.19 |
| Unhealthy Ageing | 2.4 | 1 | 1.4 |
| Vitiligo | 1.6 | 0.6 | 1.67 |
